CJC-1295 Safety Profile

Safety Overview

CJC-1295 is not FDA-approved for any use. It is a synthetic analog of growth hormone-releasing hormone (GHRH) that was evaluated in clinical trials but never achieved regulatory approval. Development was discontinued, and comprehensive safety data has never been published.

Level of Evidence: Incomplete clinical trial data, animal studies. No published Phase 3 results or long-term human safety monitoring.

Critical Confusion: Two distinct forms of CJC-1295 exist in the research peptide market:

• CJC-1295 with DAC (Drug Affinity Complex): Long-acting, extended half-life
• CJC-1295 without DAC (Modified GRF 1-29): Short-acting, often mislabeled

This creates significant safety and dosing confusion, as the two have vastly different pharmacokinetics.

Reported Side Effects from Limited Trials

Side Effect	Severity	Notes
Injection site reactions	Mild to moderate	Pain, redness, swelling at injection site
Headache	Mild	Reported in clinical subjects
Water retention	Mild to moderate	Associated with GH elevation
Flushing	Mild	Vasodilation response
Dizziness	Mild	Reported in some participants

Important: This data comes from incomplete, unpublished trial information. Full adverse event profiles were never disclosed.

Sustained Growth Hormone Elevation Risks

CJC-1295 with DAC causes prolonged elevation of growth hormone for days after a single injection, unlike natural pulsatile GH secretion. This sustained elevation raises concerns:

Metabolic Concerns

• Insulin resistance: Chronic GH elevation opposes insulin, impairing glucose control
• Hyperglycemia: May elevate blood sugar, particularly concerning for pre-diabetics
• Lipid changes: Effects on cholesterol and triglycerides unknown
• Glucose intolerance: Risk of progressing to type 2 diabetes with chronic use

Tissue Effects

• Soft tissue swelling: GH causes fluid retention and tissue expansion
• Joint pain and stiffness: Common with elevated GH, particularly hands and feet
• Carpal tunnel syndrome: Fluid retention compresses nerves
• Organomegaly concerns: Very high chronic GH can enlarge organs (heart, kidneys, liver)

Cardiovascular Unknowns

• Cardiac structure changes: GH affects heart muscle thickness and function
• Blood pressure: May increase with sustained GH elevation
• Long-term cardiovascular risk: Completely unstudied for CJC-1295

Product Quality and Variant Confusion

The unregulated CJC-1295 market has severe quality issues:

• DAC vs. non-DAC mislabeling: Products often incorrectly labeled, leading to dosing errors
• Purity concerns: No third-party verification of peptide content
• Modified GRF 1-29 substitution: Vendors sell Modified GRF as “CJC-1295 no DAC,” technically different peptides
• Contamination risk: Injectable products may contain impurities or bacterial endotoxins
• Dose inaccuracy: Labeled doses may not match actual peptide content

Unknown Long-Term Risks

Because clinical development was abandoned, critical questions remain unanswered:

Unknown Factor	Risk Consideration
Why trials stopped	Could indicate safety signals, efficacy failure, or commercial decisions
Cancer risk	GH’s role in cell proliferation raises theoretical tumor growth concerns
Pituitary effects	Long-term impact on natural GH regulation unknown
Reproductive safety	Effects on fertility, pregnancy, and development unstudied
Immune function	Potential alterations to immune response not evaluated

Contraindications (Theoretical)

Based on GH physiology, CJC-1295 should likely be avoided by:

• Individuals with active cancer or cancer history (GH may promote tumor growth)
• Diabetics or pre-diabetics (worsening glucose control)
• Those with cardiovascular disease (unknown cardiac effects)
• Pregnant or nursing women (developmental effects unknown)
• Individuals with acromegaly or pituitary disorders

Note: These are theoretical contraindications based on GH physiology, not established clinical guidelines.

Regulatory Status

• FDA Status: Not approved; classified as an unapproved drug
• Clinical Development: Discontinued; reasons not publicly disclosed
• Legal Status: Illegal to market for human consumption in the U.S.
• International: Not approved in any country for therapeutic use

CJC-1295 entered clinical trials but failed to gain approval. The product quality confusion and lack of long-term safety data present significant risks. This information is for educational purposes only and does not constitute medical advice.